Hrnciar Peter, Ueda Yasutsugu, Huang Stella, Leet John E, Bronson Joanne J
Bristol-Myers Squibb Co., Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, Connecticut 06492, USA.
J Org Chem. 2002 Dec 13;67(25):8789-93. doi: 10.1021/jo020385z.
Nocathiacin I (1) and nocathiacin IV (2) are novel indole-containing thiazolyl peptide antibiotics, which exhibit potent activity against key Gram-positive bacterial pathogens, including multi drug-resistant Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecium. New nocathiacins 7-12 were prepared from 2 by a condensation with glycolaldehyde followed by tandem reductive amination of the 2-oxoethyl intermediate 4. The latter was formed via Amadori rearrangement from initial 2-hydroxyethylideneamide 3. This transformation readily tolerates the complex architecture of nocathiacins and allows selective incorporation of water solubilizing groups to the primary amide in 2 without protecting group manipulation.